secwatch.observer — SEC 8-K summary
======================================

Issuer:     Solventum Corp (SOLV)
CIK:        0001964738
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001964738-26-000005
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Solventum reports Q4 2025 sales $2B, organic sales +3.5%; full-year adjusted EPS $6.11, down 8.8% YoY
--------------------------------------------------------------------------------

- Q4 reported sales $1,998M (-3.7% YoY); organic sales +3.5% driven by MedSurg and Dental.
- GAAP diluted EPS $0.36; adjusted diluted EPS $1.57 (+11.3% YoY).
- Full-year 2025 adjusted EPS $6.11 (down 8.8% from $6.70); free cash flow -$10M vs $805M in 2024.
- Introduced 2026 full-year guidance for organic sales growth, adjusted EPS, and free cash flow.
- CEO Bryan Hanson: full-year 2025 results ahead of expectations; solid progress toward long-range plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1964738/000196473826000005/0001964738-26-000005-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1964738/000196473826000005/solv-20260226.htm
  HTML page:      https://secwatch.observer/filing/0001964738-26-000005

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer